Pomerantz Law Firm Launches Investigation into Capricor Therapeutics for Potential Securities Fraud

Investor Alert: Pomerantz Law Firm Investigates Capricor Therapeutics

Pomerantz LLP, a well-regarded law firm based in New York, has initiated an investigation into Capricor Therapeutics, Inc., trading on NASDAQ under the symbol CAPR. This inquiry seeks to address potential claims from investors related to alleged securities fraud and misconduct by the company and its leadership. The investigation comes at a critical time as Capricor recently faced a significant setback concerning its Biologics License Application (BLA).

Background on Capricor Therapeutics

Capricor Therapeutics specializes in innovative cell therapies, most notably focusing on developing treatments for Duchenne muscular dystrophy (DMD). One of their key products, deramiocel, aims to address the heart-related complications often faced by patients suffering from DMD. The significance of this treatment cannot be overstated, as it offers hope to many patients and their families who have long awaited advancements in therapy for this challenging condition.

Recent Developments and Stock Impact

On May 5, 2025, Capricor announced a consultation with the U.S. Food and Drug Administration (FDA) regarding their application for deramiocel. The announcement stated that the FDA confirmed its intent to conduct an advisory committee meeting related to this application. This news initially led to optimism among investors. However, the following day, Capricor's stock plummeted by approximately 29.13%, dropping $3.00 per share to close at $7.30. Such volatility raises concerns regarding the disclosure practices and corporate governance at Capricor.

The Role of Pomerantz LLP

Pomerantz LLP has earned a robust reputation for its work in corporate, securities, and antitrust class litigation. Founded by legendary attorney Abraham L. Pomerantz, the firm has been a trailblazer in the field of securities class action lawsuits for over eight decades. Their experienced legal team is committed to advocating for the rights of investors who have been harmed by fraudulent practices and breaches of trust.

Danielle Peyton, a representative from Pomerantz, has stated that investors of Capricor Therapeutics are encouraged to step forward to discuss their experiences. Potential plaintiffs are advised to reach out directly to the firm via email at [email protected] or by phone at 646-581-9980, extension 7980. The firm aims to build a comprehensive understanding of the situation surrounding Capricor’s practices and to determine whether these investors have a valid claim for class action.

Conclusion

As this investigation unfolds, it remains crucial for current and potential investors in Capricor Therapeutics to stay informed about the developments surrounding the company and the ongoing inquiry by Pomerantz LLP. The outcomes of this situation could have significant implications not just for Capricor, but for the broader biopharmaceutical industry, where investor confidence is essential for ongoing innovation and the success of therapeutic advancements.

For more detailed updates, investors are encouraged to monitor Capricor’s corporate announcements and seek legal guidance to protect their interests.